GVHD characteristics and patient response to steroid treatment
| Patient response to steroids . | ||
|---|---|---|
| . | Plus single-agent PPX . | No PPX . |
| Number of patients, N | 12 | 12 |
| aGVHD | ||
| Grade 1, n (%) | 1 (8) | 2 (17) |
| Grade 2-4, n (%) | 1 (8) | 7 (58) |
| D to diagnosis, median (range) | 61 (24-97) | 41 (13-86) |
| aGVHD treatment | ||
| Systemic corticosteroids, n (%) | — | 1 (11) |
| Systemic corticosteroids and other, n (%) | 1 (50) | 6 (67) |
| Other therapies, n (%) | 1 (50) | 1 (11) |
| Complete resolution of aGVHD, n (%) | 2 (100) | 9 (100) |
| cGVHD | ||
| Mild, n (%) | 1 (8) | 2 (17) |
| Moderate to severe, n (%) | — | 3 (25) |
| cGVHD treatment | ||
| Systemic corticosteroids and CNI, n (%) | — | 2 (40) |
| Systemic corticosteroids, CNI, and other, n (%) | — | 3 (60) |
| Other therapies, n (%) | 1 (100) | — |
| Complete resolution of cGVHD, n (%) | 1 (100) | 5 (100) |
| Patient response to steroids . | ||
|---|---|---|
| . | Plus single-agent PPX . | No PPX . |
| Number of patients, N | 12 | 12 |
| aGVHD | ||
| Grade 1, n (%) | 1 (8) | 2 (17) |
| Grade 2-4, n (%) | 1 (8) | 7 (58) |
| D to diagnosis, median (range) | 61 (24-97) | 41 (13-86) |
| aGVHD treatment | ||
| Systemic corticosteroids, n (%) | — | 1 (11) |
| Systemic corticosteroids and other, n (%) | 1 (50) | 6 (67) |
| Other therapies, n (%) | 1 (50) | 1 (11) |
| Complete resolution of aGVHD, n (%) | 2 (100) | 9 (100) |
| cGVHD | ||
| Mild, n (%) | 1 (8) | 2 (17) |
| Moderate to severe, n (%) | — | 3 (25) |
| cGVHD treatment | ||
| Systemic corticosteroids and CNI, n (%) | — | 2 (40) |
| Systemic corticosteroids, CNI, and other, n (%) | — | 3 (60) |
| Other therapies, n (%) | 1 (100) | — |
| Complete resolution of cGVHD, n (%) | 1 (100) | 5 (100) |
aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD